Sun Pharma Advanced Research Company Limited

NSE SPARC.NS

Sun Pharma Advanced Research Company Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD 5.08 M

Sun Pharma Advanced Research Company Limited Net Cash Used Provided By Financing Activities is USD 5.08 M for the year ending March 31, 2024, a -93.23% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Sun Pharma Advanced Research Company Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 75.04 M, a 148.47% change year over year.
Sun Pharma Advanced Research Company Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD 30.20 M, a 38.84% change year over year.
Sun Pharma Advanced Research Company Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 21.75 M, a 195.57% change year over year.
Sun Pharma Advanced Research Company Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD 7.36 M, a -81.35% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NSE: SPARC.NS

Sun Pharma Advanced Research Company Limited

CEO	Mr. Anilkumar Raghavan
IPO Date	Jan. 14, 2003
Location	India
Headquarters	17-B, Mahal Industrial Estate
Employees	409
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited

Key trends

Past 5 years